Cash Capital co-led a series A for Vision Medicals, co-founded by faculty at the Yunnan Province Key Laboratory for Gene Editing.
China-based microbial pathogen analysis provider Vision Medicals has closed a $14m series A round co-led by Cash Capital, an investment arm of Chinese Academy of Sciences, and venture firm Volcanics Venture.
Vision Medicals is developing a technology to identify microbial pathogens in environmental samples of the kind investigated in sectors including industry, agriculture, ecology and medicine.
The approach, which falls under a branch of genomics called metagenomics, picks up pathogen traces using Vision’s nucleic acid enrichment platform matched with Crispr gene-editing technology and high-throughput screening.
Vision Medicals’ founders include its chief technology officer, Teng Xu, an adjunct professor at the Yunnan Province Key Laboratory for Gene Editing.
